Given the US Food and Drug Administration approval of poly(adenosine diphosphate) ribose polymerase (PARP) inhibitors in advanced BRCA-associated ovarian, breast, prostate, and pancreatic cancers,21,22,23,24 the identification of germline variants in BRCA1/2 may have future implications for treatment by being the basis for enrolling such patients in therapeutic studies of PARP inhibitors. The gene discussed is BRCA1; the disease is familial pancreatic carcinoma.